Axial Spondyloarthritis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis: Ankylosing Spondylitis (US)

Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness. Key treatment goals include easing the signs and symptoms of AS, improving physical function, preventing disability, and slowing or preventing structural damage. TNF-alpha inhibitors (AbbVie’s Humira, Amgen’s Enbrel, Johnson & Johnson Innovative Medicine’s Remicade and Simponi / Simponi Aria, UCB’s Cimzia, and infliximab biosimilars) can reduce disease activity in AS and are very effective for patients who require more-potent therapies beyond first-line nonsteroidal anti-inflammatory drugs (NSAIDs). Recently launched biosimilars of adalimumab offer cost-effective alternatives while maintaining efficacy and safety. The IL-17 inhibitors—Novartis’s Cosentyx and Eli Lilly’s Taltz—offer an alternative MOA to TNF inhibition. The novel JAK inhibitor class comprises Pfizer’s Xeljanz and AbbVie’s Rinvoq—the only nonbiological targeted therapies for AS.


  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed AS patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed AS patients?
  • How has Rinvoq been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of AS patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of AS patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?


Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: AbbVie, Amgen, J & J Innovative Medicine, UCB, Novartis, Eli Lilly

Key drugs: NSAIDs, Humira, Enbrel, Cimzia, Remicade, Simponi, Cosentyx, Taltz, Xeljanz, Rinvoq.


The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.

launch Related Market Assessment Reports